179 related articles for article (PubMed ID: 23242669)
1. Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.
Simoens S; Sinnaeve PR
Cardiovasc Drugs Ther; 2013 Feb; 27(1):49-60. PubMed ID: 23242669
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Hirsch M; O'Donnell JC; Jones P
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
[TBL] [Abstract][Full Text] [Related]
4. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Tran YB; Frial T; Miller PS
Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
[TBL] [Abstract][Full Text] [Related]
5. Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
Ohsfeldt RL; Gandhi SK; Fox KM; McKenney JM
Value Health; 2008 Dec; 11(7):1061-9. PubMed ID: 18489494
[TBL] [Abstract][Full Text] [Related]
6. Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective.
Straka RJ; Mamdani M; Damen J; Kuntze CE; Liu LZ; Botteman MF; Koren MJ
Curr Med Res Opin; 2007 Jul; 23(7):1517-29. PubMed ID: 17535539
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.
Annemans L; Marbaix S; Webb K; Van Gaal L; Scheen A
Clin Drug Investig; 2010; 30(2):133-42. PubMed ID: 20067331
[TBL] [Abstract][Full Text] [Related]
8. Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease.
Attanasio E; Russo P; Allen SE
Clin Ther; 2001 Feb; 23(2):276-83; discussion 274-5. PubMed ID: 11293560
[TBL] [Abstract][Full Text] [Related]
9. A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
Badia X; Russo P; Attanasio E
Clin Ther; 1999 Oct; 21(10):1788-96. PubMed ID: 10566573
[TBL] [Abstract][Full Text] [Related]
10. The value of atorvastatin over the product life cycle in the United States.
Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Usher-Smith JA; Ramsbottom T; Pearmain H; Kirby M
Int J Clin Pract; 2007 Jan; 61(1):15-23. PubMed ID: 17229176
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
Barrios V; Lobos JM; Serrano A; Brosa M; Capel M; Alvarez Sanz C
J Med Econ; 2012; 15 Suppl 1():45-54. PubMed ID: 22954062
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
Hirsch M; O'donnell J; Olsson A
Int J Cardiol; 2005 Oct; 104(3):251-6. PubMed ID: 16186052
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
[TBL] [Abstract][Full Text] [Related]
16. Generic atorvastatin and health care costs.
Jackevicius CA; Chou MM; Ross JS; Shah ND; Krumholz HM
N Engl J Med; 2012 Jan; 366(3):201-4. PubMed ID: 22149736
[No Abstract] [Full Text] [Related]
17. Managed care trends in statin usage.
Bazalo GR
Manag Care; 2001 Oct; 10(10):48-50, 53-9. PubMed ID: 11688111
[TBL] [Abstract][Full Text] [Related]
18. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom.
Buller N; Gillen D; Casciano R; Doyle J; Wilson K
Pharmacoeconomics; 2003; 21 Suppl 1():25-32. PubMed ID: 12648032
[TBL] [Abstract][Full Text] [Related]
19. [Atorvastatin (Lipitor)].
Carpentier Y; Ducobu J; Sternon J
Rev Med Brux; 1999 Oct; 20(5):427-33. PubMed ID: 10582478
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
